medicina58巻10号

2021年09月発行

特集 腎疾患—エキスパートへの質問で学ぶ診療のキホンと最新情報 膠原病

全身性エリテマトーデス診療の基本と最新治療を教えてください

著者： 木戸口元気¹ 岡田正人¹

所属機関： ¹聖路加国際病院Immuno-Rheumatology Center

ページ範囲：P.1560 - P.1565

Point
◎膠原病診療の基本は「病態診断→除外診断→臨床診断→治療・フォローアップ」である．
◎臨床経過，検査所見から，腎組織型を予測する．ループス腎炎の組織型に応じて，免疫抑制治療の適応を判断する．
◎活動性のループス腎炎に対するベリムマブの有用性を証明した大規模RCTが2020年に報告された．標準療法への追加が検討される．

参考文献

1）Firestein GS, et al：Kelly and Firestein's Textbook of Rheumatology, 10th Edition, Elsevier, Philadelphia, 2016

2）Hochberg MC：Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40：1725, 1997

3）Petri M, et al：Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64：2677-2686, 2012

4）Aringer M, et al：2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71：1400-1412, 2019

5）Adamichou C, et al：In an early SLE cohort the ACR-1997, SLICC-2012 and EUt AR,/ACR-2019 criteria classily non-overlapping groups of patients；Use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 79：232-241, 2020

6）Suda M, et al：Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erlthematosus in 100 Japanese patients ;A real-world setting analysis. Clin Rheumatol 39：1823-1827, 2020

7）Takehiro N, et al：Risk of adverse pregnancy outcomes in Japanese systemic lupus erythematosus patients with prior severe organ manifestations；A single-center retrospective analysis. Lupus, 2021（article in press）

8）厚生労働科学研究費補助金難治性疾患等制作研究事業 自己免疫疾患に関する調査研究：全身性エリテマトーデス診療ガイドライン2019，南江堂，2019

9）Fanouriakis A, et al：2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association（EULAR/ERA-EDTA）recommendations for the management of lupus nephritis. Ann Rheum Dis Jun 79：713-723, 2020

10）Fanouriakis A, et al：Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80：14-25, 2021

11）Kitamura N, et al：Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin Ⅱ receptor blocker in patients with lupus nephritis. J Int Med Res 37：892-898, 2009

12）Yu HH, et al：Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia；A nationwide population-based cohort study. Artherosclerosis 243：11-18, 2015

13）Alarcón GS, et al：Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus ;Data from LUMINA, a multicenthnic US cohort（LUMINA L）. Ann Rheum Dis 66：1168-1172, 2007

14）Melles RB, et al：The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Opthalmol 132：1453-1460, 2014

15）Chan TM, et al：Eficcacy of mycophenolate mofetil in patietns with diffuse proliferative lupus nephritis. Hong-Kong-Guangzhour Nephrology Study Group. N Engl J Med 343：1156-1162, 2000

16）Dooley MA, et al：Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365：1886-1895, 2011

17）Liu Z, et al：Multitarget therapy for Induction treatment of lupus nephritis；A randomized, controlled trial. Ann Intern Med 162：18-26, 2015

18）Furie R, et al：Two-year randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383：1117-1128, 2020

19）Takehiro N, et al：Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus；A single-center retrospective analysis. Clinical Rheumatology 39：3653-3659, 2020